IMMUNE NETWORK

  • 제21권4호
  • /
  • Pages.29.1-29.9
  • /
  • 2021
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines

  • Ji Yeun Kim (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Seongman Bae (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Soonju Park (Institut Pasteur Korea) ;
  • Ji-Soo Kwon (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • So Yun Lim (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ji Young Park (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hye Hee Cha (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Mi Hyun Seo (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hyun Jung Lee (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Nakyung Lee (Institut Pasteur Korea) ;
  • Jinyeong Heo (Institut Pasteur Korea) ;
  • David Shum (Institut Pasteur Korea) ;
  • Youngmee Jee (Institut Pasteur Korea) ;
  • Sung-Han Kim (Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2021.07.09
  • 심사 : 2021.08.13
  • 발행 : 2021.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

There are limited data directly comparing humoral and T cell responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines. We compared Ab and T cell responses after first doses of ChAdOx1 nCoV-19 vs. BNT162b2 vaccines. We enrolled healthcare workers who received ChAdOx1 nCoV-19 or BNT162b2 vaccine in Seoul, Korea. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S1 protein-specific IgG Abs (S1-IgG), neutralizing Abs (NT Abs), and SARS-CoV-2-specific T cell response were evaluated before vaccination and at 1-wk intervals for 3 wks after vaccination. A total of 76 persons, comprising 40 injected with the ChAdOx1 vaccine and 36 injected with the BNT162b2 vaccine, participated in this study. At 3 wks after vaccination, the mean levels (±SD) of S1-IgG and NT Abs in the BNT162b2 participants were significantly higher than in the ChAdOx1 participants (S1-IgG, 14.03±7.20 vs. 6.28±8.87, p<0.0001; NT Ab, 183.1±155.6 vs. 116.6±116.2, p=0.035), respectively. However, the mean values of the T cell responses in the 2 groups were comparable after 2 wks. The humoral immune response after the 1st dose of BNT162b2 developed faster and was stronger than after the 1st dose of ChAdOx1. However, the T cell responses to BNT162b2 and ChAdOx1 were similar.

키워드

과제정보

This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, which is funded by the Ministry of Health & Welfare, Republic of Korea (grant No. HW20C2062) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2017M3A9G6068254).

참고문헌

  1. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-478. https://doi.org/10.1016/S0140-6736(20)31604-4
  2. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015;217:345-351. https://doi.org/10.1016/j.jconrel.2015.08.007
  3. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020;383:2439-2450. https://doi.org/10.1056/NEJMoa2027906
  4. Kalimuddin S, Tham CYL, Qui M, de Alwis R, Sim JXY, Lim JME, Tan HC, Syenina A, Zhang SL, Le Bert N, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y) 2021;2:682-688.e4. https://doi.org/10.1016/j.medj.2021.04.003
  5. Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis 2021;ciab381.
  6. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermudez-Gonzalez MC, Bielak DA, Carreno JM, Chernet RL, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021;384:1372-1374. https://doi.org/10.1056/NEJMc2101667
  7. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020;586:578-582. https://doi.org/10.1038/s41586-020-2608-y
  8. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines 2021;6:74.
  9. Giurgea LT, Memoli MJ. Navigating the quagmire: comparison and interpretation of COVID-19 vaccine phase 1/2 clinical trials. Vaccines (Basel) 2020;8:746.
  10. Rogliani P, Chetta A, Cazzola M, Calzetta L. SARS-CoV-2 neutralizing antibodies: a network meta-analysis across vaccines. Vaccines (Basel) 2021;9:227.
  11. Kim JY, Kwon JS, Bae S, Cha HH, Lim JS, Kim MC, Chung JW, Park SY, Lee MJ, Kim BN, et al. SARS-CoV-2-specific antibody and T cell response kinetics according to symptom severity. Am J Trop Med Hyg 2021;tpmd201594.
  12. Classen DC, Morningstar JM, Shanley JD. Detection of antibody to murine cytomegalovirus by enzyme-linked immunosorbent and indirect immunofluorescence assays. J Clin Microbiol 1987;25:600-604. https://doi.org/10.1128/jcm.25.4.600-604.1987
  13. Lardeux F, Torrico G, Aliaga C. Calculation of the ELISA's cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls. Mem Inst Oswaldo Cruz 2016;111:501-504. https://doi.org/10.1590/0074-02760160119
  14. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396:1979-1993. https://doi.org/10.1016/S0140-6736(20)32466-1
  15. Hasanpourghadi M, Novikov M, Ertl HC. COVID-19 vaccines based on adenovirus vectors. Trends Biochem Sci 2021;46:429-430. https://doi.org/10.1016/j.tibs.2021.03.002
  16. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997;94:3352-3356. https://doi.org/10.1073/pnas.94.7.3352
  17. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998;72:415-419. https://doi.org/10.1128/JVI.72.1.415-419.1998
  18. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stoter M, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013;31:638-646. https://doi.org/10.1038/nbt.2612
  19. Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther 2019;27:757-772. https://doi.org/10.1016/j.ymthe.2019.01.020
  20. Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol 2016;41:18-22. https://doi.org/10.1016/j.coi.2016.05.008
  21. Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther 2018;26:446-455. https://doi.org/10.1016/j.ymthe.2017.11.017
  22. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, Rawlings SA, Smith DM, Phillips E, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020;370:89-94. https://doi.org/10.1126/science.abd3871
  23. Schmidt KG, Nganou-Makamdop K, Tenbusch M, El Kenz B, Maier C, Lapuente D, uberla K, Spriewald B, Bergmann S, Harrer EG, et al. SARS-CoV-2-seronegative subjects target CTL epitopes in the SARS-CoV-2 nucleoprotein cross-reactive to common cold coronaviruses. Front Immunol 2021;12:627568.